Snellman, Anniina
Ekblad, Laura L.
Tuisku, Jouni
Koivumäki, Mikko
Ashton, Nicholas J.
Lantero-Rodriguez, Juan
Karikari, Thomas K.
Helin, Semi
Bucci, Marco
Löyttyniemi, Eliisa
Parkkola, Riitta
Karrasch, Mira
Schöll, Michael
Zetterberg, Henrik
Blennow, Kaj
Rinne, Juha O.
Article History
Received: 29 September 2022
Accepted: 13 March 2023
First Online: 4 April 2023
Declarations
:
: The study was approved by the Ethical Committee of the Hospital District of Southwest Finland. All participants signed a written informed consent according to the Declaration of Helsinki.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. MS has served on a scientific advisory board for Servier Pharmaceuticals (outside submitted work). AS, LLE, JT, MKo, NJA, JL, TKK, SH, MB, MKa, EL, RP, and JR report no competing interests.